Singapore’s Breathonix has said a clinical trial of its COVID-19 breathalyzer test was able to achieve at least 90% accuracy after screening participants on-site for 60 seconds.
The company’s test uses mass spectrometry to analyze the thousands of volatile organic compounds that people exhale with every breath, to establish a specific signal among those with an active coronavirus infection.
By incorporating disposable mouthpieces and one-way valves, the company said its breathalyzer system could potentially be used for mass screening in high-traffic areas, such as airports, hotels, sports venues and transportation hubs. In addition, Breathonix estimated the total cost could reach $20 per test.
.
.
.